Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder
Completed
Massachusetts General Hospital
Phase 4
2005-06-01
The purpose of this study is to obtain data investigating the safety and efficacy of
eszopiclone for the treatment of post-traumatic stress disorder (PTSD)-related sleep
disturbance and the impact of improved sleep with eszopiclone treatment on neuroendocrine
correlates of PTSD. The investigators hypothesize that eszopiclone will be significantly more
effective than placebo and well tolerated for PTSD-related sleep disturbance, improvement in
sleep will be associated with improvement in overall PTSD symptoms, and patients with
PTSD-related sleep disturbances will have abnormal levels of stress hormones.
Testing the Nocturnal Sleep Latency Profile in Primary Insomnia
Completed
American Academy of Sleep Medicine
2005-01-01
This study tests a new kind of sleep study in which subjects are awakened 2 times after
initially going to sleep. The study focuses on the EEG signal process as a person goes to
sleep. The general hypothesis is that the signal properties are stable from night to night
during baseline studies, and are different between controls and patients with primary
insomnia. The primary insomnia patients then go on to have about 2 weeks of an insomnia
intervention. Then the new kind of study is repeated in the patients. The controls only are
examined in baseline studies.
Testing the Nocturnal Sleep Latency Profile in Primary Insomnia
Completed
Sunovion
2005-01-01
This study tests a new kind of sleep study in which subjects are awakened 2 times after
initially going to sleep. The study focuses on the EEG signal process as a person goes to
sleep. The general hypothesis is that the signal properties are stable from night to night
during baseline studies, and are different between controls and patients with primary
insomnia. The primary insomnia patients then go on to have about 2 weeks of an insomnia
intervention. Then the new kind of study is repeated in the patients. The controls only are
examined in baseline studies.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
